Neuphoria Therapeutics Inc. Common Stock (NEUP)
StalwartFairStock Score: 68/100 — STEADY
Key Financials
| Current Price | $4.73 |
| Market Cap | $26M |
| P/E Ratio | -6.86 |
| ROE | -62.9% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Conservative balance sheet with debt-to-equity of just 0.00, providing financial flexibility
- Healthy net profit margin of 17.6% showing consistent profitability
Concerns
- Altman Z-Score of -2.7 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
Neuphoria Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $26 million. The business generates $15 million in annual revenue with a 17.6% net margin. From a quality standpoint, Neuphoria shows distressed Altman Z-Score of -2.7 warrants caution and negative ROE indicating losses. Growth dynamics show profit growth of 195.9%. Our composite FairStock Score of 68/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer